drugset / Trial / NCT02634853

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853 ↗

Phase 3 Completed 429 enrolled Mimetogen Pharmaceuticals USA, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

Timeline

Start
2015-12
Primary completion
2017-02
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tavilermide Protein / enzyme biologic 1 % —

Indications